Brief communication: Better ways to question patients about adverse medical events. A randomized, controlled trial

Annals of Internal Medicine

Volumn 144, Issue 4, 2006, Pages 257-261

  Bent, Stephen ^a,b   Padula, Amy ^a,b   Avins, Andrew L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; HEALTH HAZARD; HEART DISEASE; HUMAN; HYPERTENSION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MASS COMMUNICATION; OPEN ENDED QUESTIONNAIRE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SELF REPORT; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT; AGED; DRUG THERAPY; MIDDLE AGED; QUESTIONNAIRE; STANDARD;

AGED; DRUG THERAPY; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; SINGLE-BLIND METHOD;

EID: 33644906137     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-144-4-200602210-00007     Document Type: Article

References (13)

1. U.S. Food and Drug Administration. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting 1995. Accessed at www.fda.gov/cder/guidance/iche2a.pdf on 29 September 2005.
2. Gotzsche PC. Non-steroidal anti-inflammatory drugs. BMJ. 2000;320:1058-61.
3. National Center for Complementary and Alternative Medicine. Clinical Trial: Saw Palmetto Extract in Benign Prostatic Hyperplasia. National Institutes of Health; 2005. Accessed at http://clinicaltrials.gov/show/ NCT00037154 on 29 September 2005.
4. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002;190:583-92.
5. Ethgen M, Boutron I, Baron G, Giraudeau B, Sibilia J, Ravaud P. Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med. 2005;143:20-5.
6. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Engl J Med. 1968;279:678-9.
7. Wallin J, Sjovall J. Detection of adverse drug reactions in a clinical trial using two types of questioning. Clin Ther. 1981;3:450-2.
8. Wallander MA, Dimenas E, Svardsudd K, Wiklund I. Evaluation of three methods of symptom reporting in a clinical trial of felodipine. Eur J Clin Pharmacol. 1991;41:187-96.
9. Lapierre YD. Évaluation des effets secondaires chez les névrotiques - un essai avec la mesoridazine et le placebo. Can Psychiatr Assoc J. 1975;20:61-6.
10. Greenblatt M. Controls in clinical research. Clin Pharmacol Ther. 1964;5:864.
11. Downing RW, Rickels K, Meyers F. Side reactions in neurotics. I. A comparison of two methods of assessment. J Clin Pharmacol J New Drugs. 1970;10:289-97.
12. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-94.
13. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781-8.